Introduction
Proliferation of mammalian cells is driven by the sequential activation of different members of the Cyclin-dependent kinase (Cdk) family, which are serine/threonine kinases. The Cdk holoenzyme is composed of a regulatory subunit, called Cyclin, and a catalytic subunit, Cyclin-dependent kinase (CDK). Cdk kinase complexes are formed and activated at specific stages of the cell cycle, and their activities are required for progression through distinct cell cycle phases. Progression through G 1 and entry into S phase are regulated by the Cyclin A±Cdk2 and Cyclin E±Cdk2 complexes, respectively, and the G 2 /M phase transition is driven by Cyclin B±Cdc2. These Cyclin±Cdk complexes often bind to the endogenous inhibitor proteins (CKIs) p21
WAF1aCIP1 and p27 KIP1 , which inhibit their kinase activities and prevent cell cycle progression (reviewed in refs 1,2). Thus, CKIs are thought to be good target molecules for the development of anticancer agents that can selectively control the cell cycle in cancer cells (3, 4) . In the present study, we explored a novel type of anticancer agent that can selectively block cell cycle events and therefore suppress cancer cell growth by specifically blocking Cyclin±Cdk activity in these cells. To this end, we examined whether certain ginsenosides, which are ginseng saponins isolated from the root of ginseng, Panax ginseng C.A. Meyer, can induce CKI protein synthesis and thereby inhibit Cyclin±Cdk activity in cancer cell lines including SK-HEP1 and HeLa cells. In our earlier reports, we showed that the diol-type ginsenosidesRs3 and -Rs4 selectively elevate p53 and p21
WAF1aCIP1 levels and consequently down-regulate the activity of Cyclins E-and A±Cdk2 in SK-HEP1 cells (5±7). In this study, we further explored whether other types of ginsenosides can selectively interfere with cell cycle progression in human cancer cell lines. Panaxadiol (PD) is a pseudoaglycone of diol-type ginsenoside that structurally differs from ginsenosides-Rs3 and Rs4 in the side chain and carbohydrate moiety that are bound to the dammarane skeleton ( Figure 7 ). In the present study, we demonstrate that PD can selectively inhibit Cyclin A±Cdk2 activity by elevating levels of the p21
WAF1aCIP1 that is associated with the Cyclin A±Cdk2 complex. Consequently, PD suppresses cell growth in the human HeLa and SK-HEP1 cancer cell lines by selectively arresting the cell cycle at G 1 /S phase.
Materials and methods

Materials
PD was prepared from the acid-hydrolysate of butanol-soluable fraction of ginseng. Dulbecco's modified Eagle's medium and calf serum were obtained from Life Technologies (Palo Alto, CA). General chemicals were purchased from Sigma (St Louis, MO). [g-32 P]ATP was purchased from Amersham Pharmacia Biotech (Uppsala, Sweden).
Cell culture
HeLa cells and SK-HEP-1 cells were obtained from Seoul National University Cancer Center and maintained as a monolayer culture in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% (by volume) heatinactivated calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.
[ 3 H]Thymidine incorporation assay
HeLa and SK-HEP-1 cells were plated at a density of 2.5 Â 10 4 cells onto 24 well plates in 1 ml 5% CS-DMEM. Twenty-four hours after seeding, cells were incubated with 0.5% CS-DMEM containing varying concentration of PD and 0.5 mCi [ 3 H]thymidine for 24 h. At the end of the incubation, unincorporated [
3 H]thymidine was removed by washing cells with phosphate buffered saline (PBS). Cells were then fixed with trichloroacetic acid, digested with 0.2 N NaOH/0.5% SDS, and incorporated radioactivity was quantified by a liquid scintillation counter (Wallac, Sweden).
Flow cytometry analysis
HeLa cells were plated at density of 1 Â 10 5 cells/60 mm dish and cultured in 5% calf-serum containing DMEM, and treated with or without 5 mM PD containing DMEM for increased times. At the end of incubation, cells were trypsinized and fixed with 75% ethanol and stored at 4 C until analysis. Cells were suspended in DAPI solution (Partec, Germany) and cell cycle analysis was performed using a flow cytometer (Partec, Germany). Immunoprecipitation and histone H1 kinase assay An aliquot (500 mg of protein) from each cell extract was pre-cleared with protein A±agarose beads (Upstate Biotechnology), and the supernatant was incubated with polyclonal rabbit antibodies to Cyclin A for 4 h. Immunecomplexes associated with Cyclin A were collected after incubating for 2 h with protein A±agarose beads. The immune-complexes were then resolved by SDS±PAGE and analyzed for their components by immunoblotting using corresponding mouse monoclonal antibodies. Immune-complexes of Cdk2, Cdc2, Cyclin A and Cyclin E were obtained from aliquots (200 mg of protein) of each cell extract by immunoprecipitating with specific antibodies against Cdk2, Cdc2, Cyclin A and Cyclin E, respectively. Each immune-complex was washed three times with IP lysis buffer and twice with kinase assay buffer containing 50 mM Tris pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 1 mM EGTA, 50 mM b-glycerol phosphate, 25 mM NaF, 0.1 mM Na 3 VO 4 , 1 mg/ml leupeptin, 1 mg/ml pepstatin A, 1 mg/ml antipain and 1 mM PMSF. The immunecomplexes were then incubated for 15 min at 30 C in 50 ml kinase assay buffer supplemented with 5 mg histone H1 (Gibco BRL, Carlsbad, CA), 10 mCi [g-32 P]ATP (10 mM), 5 mM PKI and 20 mM EGTA, and the proteins were resolved on a 12% SDS±PAGE. Cyclin-associated kinase activities were then determined by autoradiography. Panaxadiol down-regulates the activity of Cyclin A-dependent Cdk2 As PD arrests the cell cycle in G 1 /S phase, we investigated whether this arrest results from the selective inhibition of the Cyclin±Cdk2 activity that is responsible for cell cycle progression. An immune-complex kinase assay showed that Cyclin±Cdk2 activity is selectively down-regulated in a dosedependent manner while Cyclin±Cdc2 activity remains unaltered even at a dose (10 mM) of PD ( Figure 3A ) that is high enough to completely arrest cell growth ( Figure 1 ). We next examined whether either Cyclin A-or Cyclin Edependent Cdk2 activity is selectively suppressed in PDtreated HeLa cells. An immune-complex assay showed that Cyclin A-dependent kinase activity, but not Cyclin Edependent kinase activity, is significantly down-regulated in PD-treated HeLa cells ( Figure 3B ). These findings suggest that the selective inhibition of Cyclin A±Cdk2 activity is responsible for the cell cycle arrest at G 1 /S phase in PD-treated HeLa cells. To rule out the possibility that PD directly inhibits Cyclin A±Cdk2 activity, we performed an in vitro kinase assay with the Cyclin A±Cdk2 kinase immune-complex. The results showed that Cyclin A±Cdk2 kinase activity is not detectably altered by incubation with increasing concentrations (up to 20 mM) of PD, while the positive control, roscovitine (1 mM), a known inhibitor of Cdk2 and Cdc2 kinases (8) , effectively inhibits Cyclin A±Cdk2 activity ( Figure 3C ). Thus, the inhibitory effect of PD on Cyclin A±Cdk2 activity appears to be mediated through an indirect action, such as by the modulation of upstream signals.
Results
Panaxadiol
Down-regulation of Cyclin A±Cdk2 activity is attributed to elevated p21
WAF1aCIP1 levels in PD-treated cells To elucidate the mechanism by which Cyclin A±Cdk2 activity is down-regulated in PD-treated HeLa cells, we examined whether the levels of the different protein components of the Cyclin A±Cdk2 complex are altered following PD treatment (Figure 4) . The immunoblots indicated that the levels of Cyclin A, Cdk2, Cyclin E and Cdc2 remained unaltered in cells treated with increasing concentrations of PD (Figure 4) . Interestingly, however, p21
WAF1aCIP1 levels were markedly elevated in a PD dose-dependent manner, and they were 8±9-fold higher in cells treated with 10 mM PD compared with vehicle-treated cells. In contrast, p27 KIP1 levels were unchanged under the same experimental conditions. Additionally, p21
WAF1aCIP1 levels were detectably elevated 8 h after treatment with 5 mM PD, a concentration that is sufficient to arrest the cell cycle at G 1 /S phase as determined by flow 
cytometry. Furthermore, p21
WAF1aCIP1 levels gradually increased in a time-dependent fashion in PD-treated cells ( Figure 5A ), while the levels of the other components remained unchanged. These results strongly suggest that the down-regulation of Cyclin A±Cdk2 activity can be primarily attributed to elevated p21
WAF1aCIP1 levels following PD treatment. To provide direct evidence that increased p21
WAF1aCIP1 levels are responsible for the down-regulation of Cyclin A±Cdk2 activity, we examined whether levels of the p21
WAF1aCIP1 protein that is directly associated with the Cyclin A±Cdk2 complex are also increased following PD treatment. Immunoblotting analysis of the Cyclin A-immunecomplex indicated that levels of p21
WAF1aCIP1 protein associated with the Cyclin A±Cdk2 complex are significantly elevated in a PD dose-dependant manner ( Figure 5B ). As expected, the levels of the p27 KIP1 and Cdk2 proteins that are associated with the immune-complex were not changed. Thus, the selective down-regulation of Cyclin A±Cdk2 activity in PD-treated cells can be mainly attributed to elevated p21
WAF1aCIP1 protein levels. Collectively, the data suggest that PD arrests the cell cycle at G 1 /S phase by selectively down-regulating Cyclin A±Cdk2 activity by a mechanism that elevates p21
WAF1aCIP1 protein levels.
Discussion
In the present study, we have described the mechanism of action by which PD, a diol-type of ginseng saponin with a dammarane skeleton, arrests growth of HeLa cells at G 1 /S phase. As determined by a In contrast, asynchronous control cells normally proceed to cell cycle progression during these time periods. These results suggest that PD inhibits cell proliferation by specifically blocking the cell cycle at G 1 /S phase. It is well documented that progression through the G 1 /S transition and S phase is governed by the Cyclin±Cdk2 kinases (3). Cdk2 activity is positively controlled by the levels of its regulatory subunits, Cyclin A and Cyclin E, and negatively regulated by levels of the endogenous Cyclin-dependent 
kinase inhibitor proteins p21
WAF1aCIP1 and p27 KIP1 . To examine whether PD induces cell cycle arrest at G 1 /S phase by modulating Cdk2 activity, we determined the Cdk2 and Cdc2 activity in HeLa cells following PD treatment. Interestingly, Cyclin A±Cdk2 activity, but not Cyclin E-Cdk2 or Cdc2 activity, was selectively down-regulated in PD-treated HeLa cells ( Figure 3A and B) . This observation agrees well with the result from the flow cytometric analysis that showed that HeLa cell growth is arrested at G 1 /S phase in response to PD treatment, because Cyclin A±Cdk2 kinase activity, but not the Cyclin E± Cdk2 or Cdc2 kinase activity, is responsible for progression through S phase (1,2,8) .
In vitro immune-complex kinase assays showed that Cyclin A±Cdk2 activity is not detectably inhibited by incubation with increasing PD doses (up to 20 mM), while roscovitine, a specific Cdk2 kinase inhibitor, effectively inhibits the kinase activity at 1 mM ( Figure 3C ). Therefore, we ruled out the possibility that PD directly inhibits Cyclin A±Cdk2 activity. These results indicate that the down-regulation of Cyclin A± Cdk2 activity in PD-treated cells can be attributed to indirect mechanisms. To elucidate these mechanisms, we first determined whether the levels of the components that constitute the Cdk2 complexes are altered. The results showed that levels of Cyclins A and E, Cdk2 and Cdc2 are not altered following treatment with increasing doses of PD. Interestingly, p21
WAF1aCIP1 levels, but not p27 KIP1 levels, are selectively elevated in a PD concentration-dependent fashion (Figure 4) . This idea is supported by the results that show that p21
WAF1aCIP1 levels are detectably elevated 8 h after treatment and thereafter, markedly increased in a time-dependent manner ( Figure 5A ). In addition, the time course of p21 WAF1aCIP1 elevation correlates well with that of the G 1 /S phase-arrest of HeLa cells following PD treatment (Figure 2 ). p21
WAF1aCIP1 belongs to the CIP/KIP family of endogenous Cdk inhibitors, which regulate Cdk2 activity through direct binding (10) . Recent studies have shown that the most potent inhibitory activity of p21
WAF1aCIP1 against Cdk2 resides in amino acids 139±164 (11) and that this portion can directly bind to Cyclin A but not to Cyclin E (12) . Thus, it is thought that p21 WAF1aCIP1 more potently inhibits Cyclin A±Cdk2 activity than Cyclin E± Cdk2 activity. This result may explain our observations that Cyclin A±Cdk2 activity, but not Cyclin E±Cdk2 activity, is significantly down-regulated under the conditions in which 
(B) p21
WAF1aCIP1 associated with Cyclin A±Cdk2 is increased in PD-treated cells. Cell lysates were prepared as described in Figure 4 , and were immunoprecipitated with a polyclonal antibody to human Cyclin A. Immune-complexes were resolved by SDS±PAGE and analyzed by immunoblotting using specific monoclonal antibodies to Cyclin A, Cdk2, p27 KIP1 and p21 WAF1aCIP1 .
p21
WAF1aCIP1 levels are elevated in PD-treated cells. Furthermore, levels of the p21
WAF1aCIP1 protein that is associated with the Cyclin A±Cdk2 complex are markedly elevated in a PD dose-dependent manner, while those of other components in the immune-complex including Cyclin A, Cdk2 and p27
KIP1
are not altered. These results clearly support the idea that the PD-induced down-regulation of Cyclin A±Cdk2 activity can be primarily attributed to elevated p21
WAF1aCIP1 levels. To support this idea, we tested if PD-induced cell cycle arrest and Cyclin A±Cdk2 activity inhibition might be recovered after withdrawal of PD from the culture medium. The results suggest that the down-regulated Cdk2 activity in cells treated with 5 mM PD is effectively recovered in an incubation timedependent fashion almost to levels of the untreated-control cells ( Figure 6A and B) . Importantly, protein levels of Cdk2-associated p21
WAF1aCIP1 that have been induced in response to 5 mM PD treatment decreased to the control levels after the PD-withdrawal ( Figure 6C ). These results support the notion that PD-induced cell cycle arrest is attributed to the downregulated Cdk2 activity by inducing p21
WAF1aCIP1 levels and this arresting effect is recovered by withdrawal of PD from the culture medium.
Our earlier reports have shown that ginsenosides-Rs3 (GRs3) and -Rs4 (G-Rs4), which are different types of ginseng saponins, can induce cell cycle arrest in human hepatoma SK-HEP1 cells, and that this is associated with the selective elevation of p21
WAF1aCIP1 . Interestingly, PD is structurally different from G-Rs3 and G-Rs4: the side chain of PD at C-20 is cyclized, whereas those of G-Rs3 and G-Rs4 are open and straight, and the ±OH at C-3 of PD is free, while those of G-Rs3 and GRs4 are attached to acetylated Glc-Glc (Figure 7) . However, these three ginsenosides are structurally similar in that they share a common dammarane skeletal structure with ±OH groups attached at C-3 and C-12. It is interesting to note that panaxatriol has the same dammarane skeleton as PD, but neither exhibits cell cycle-arresting activity nor down-regulation of Cyclin-associated kinase activity (data not shown here). PD structurally differs from panaxatriol at C-6(±OH). It is speculated that the ±OH groups attached to C-3 and C-12 are functionally important, but the additional ±OH group at C-6 in panaxatriol may exhibit an opposite effect. These structural features may explain why the diol-type of ginsenosides such as G-Rs3, G-Rs4 and PD all elevate p21
WAF1aCIP1 levels and thereby down-regulate the activities of Cyclin-dependent kinases. . Cdk2 activity is effectively recovered after PD-withdrawal from the culture medium. Cells were plated and cultured in DMEM containing 5% calf-serum and treated for 24 h with 5 mM of PD in DMEM. PD-containing medium was then replaced with 5% CS-containing DMEM. Cells were thereafter harvested at 12 and 24 h. (A) Restoration of Cdk2 activity and levels of Cdk2-associated p21
WAF1aCIP1 protein were determined by an immuno-complex kinase assay and immunoblot assay, respectively. (B) Densitometric representation of the relative Cdk2 activity to control value. (C) Protein levels of Cdk2-associated p21
WAF1aCIP1 were densitometrically analyzed and presented as the relative protein levels to the control value. Lanes: 1, control; 2, vehicle control; 3, 24 h treatment with 5 mM PD; 4, control for 12 h recovery; 5, 12 h recovery of 5 mM PD treatment; 6, control for 24 h recovery; 7, 24 h recovery of 5 mM PD treatment.
In conclusion, we suggest that PD, a pseudoaglycone of dioltype ginsenosides, displays an anti-proliferative activity by arresting the cell cycle at G 1 /S phase. This effect is potentially achieved through the down-regulation of Cyclin A±Cdk2 kinase activity, which is tightly associated with elevated p21
WAF1aCIP1 levels in PD-treated cells. We therefore propose that PD can be used to arrest the cell cycle at G 1 /S phase through the selective elevation of p21
WAF1aCIP1 levels in various types of cancer cells.
